Every 8-K that Phathom Pharmaceuticals, Inc. (PHAT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PHAT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PHAT filings page.
Phathom Pharmaceuticals reported strong second-quarter 2026 results, led by product revenue of 74,274 (in thousands) for the three months ended June 30, 2026, up from 39,503 (in thousands) a year earlier. Gross profit rose to 59,178 (in thousands), and management highlighted record quarterly revenue and operating profitability when excluding non-cash stock-based compensation.
GAAP net loss narrowed to 17,582 (in thousands), or 0.21 per share, compared with 75,810 (in thousands), or 1.05 per share, in the prior-year quarter. Non-GAAP adjusted net loss was 130 (in thousands), a much smaller loss than 56,498 (in thousands) a year earlier. Cash and cash equivalents increased to 182,478 (in thousands) as of June 30, 2026. Updated 2026 guidance calls for net revenue of $310–325 million and non-GAAP operating expenses of $235–245 million, while maintaining expectations for a 55-59% gross-to-net discount and approximately 80% gross margin.
Phathom Pharmaceuticals filed an update on its drug development program, confirming it has completed enrollment in its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA (vonoprazan) tablets for adults with eosinophilic esophagitis (EoE). The study has enrolled 95 patients across 41 U.S. sites, with topline results expected in the fourth quarter of 2026.
The randomized, double-blind, placebo-controlled study gives patients VOQUEZNA 20 mg or placebo once daily for 12 weeks, followed by an optional 12-week extension phase where all receive VOQUEZNA. If results are positive, Phathom plans to discuss future development in EoE with the FDA, including a potential pediatric program that could support an extension of VOQUEZNA’s regulatory exclusivity.
Phathom Pharmaceuticals, Inc. reported voting results from its 2026 Annual Meeting of Stockholders held on May 19, 2026. Stockholders elected Class I directors Steven Basta, Theodore R. Schroeder, and Mark Stenhouse to three-year terms expiring at the 2029 annual meeting.
Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026, with 64,482,757 votes for and limited opposition. In an advisory vote, stockholders approved the compensation of the company’s named executive officers, with 44,449,761 votes for and 2,532,145 against. No other matters were brought to a vote.
Phathom Pharmaceuticals reported strong first quarter 2026 momentum as it continues its shift to gastrointestinal (GI) markets. Net product revenue reached $58.3 million, more than double the prior year’s first quarter, driven by growing VOQUEZNA prescriptions among GI specialists.
Gross profit was $46.3 million, and operating loss narrowed sharply to $15.5 million from $78.9 million a year earlier as total operating expenses fell to $61.8 million, with selling, general and administrative costs dropping to $54.0 million. On a non-GAAP basis, adjusted net loss improved to $14.7 million, or $0.18 per share.
Phathom ended March 31, 2026 with $180.9 million in cash and cash equivalents and continues to carry a stockholders’ deficit. Management reiterated full-year 2026 guidance and expects to achieve operating profitability beginning in the third quarter and for the full year 2026, and to reach cash flow positivity in 2027.
Phathom Pharmaceuticals reported strong revenue growth but continued losses for the fourth quarter and full year 2025. Net product revenue reached $57.6 million in the fourth quarter, up from $29.7 million a year earlier, and $175.1 million for 2025 versus $55.3 million in 2024.
Full-year operating expenses fell to $312.5 million from $324.7 million, and the GAAP net loss narrowed to $221.2 million from $334.3 million. Cash and cash equivalents were $130.0 million at December 31, 2025, compared with $297.3 million a year earlier, while total liabilities increased and stockholders’ deficit deepened.
Management highlighted VOQUEZNA commercial momentum, a sales force realignment, and a January financing followed by a term loan modification to reduce interest and extend maturity. The company stated that it is positioning for anticipated operating profitability in the third quarter 2026 and to reach cash flow positivity in 2027, supported by tighter expense discipline and revenue growth.
Phathom Pharmaceuticals is raising capital through an underwritten public offering of 6,875,000 shares of common stock at $16.00 per share and pre-funded warrants to purchase 1,250,078 shares at $15.999 per warrant. The underwriters also have a 30-day option to buy up to 1,218,761 additional shares at the public price, less discounts and commissions.
The company expects to receive approximately $130 million in net proceeds from the offering, or about $150 million if the option is fully exercised, before fees and expenses. The pre-funded warrants have a $0.001 exercise price, are immediately exercisable, do not expire, and include a beneficial ownership cap of up to 19.99% of outstanding common stock, which holders can adjust within that limit subject to notice.
Phathom Pharmaceuticals, Inc. filed a current report to disclose that it has issued a press release with certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The company states that this press release, dated January 7, 2026, is included as an exhibit and incorporated by reference into its securities law filings, making the early 2025 figures part of its official disclosure record.
Phathom Pharmaceuticals announced the first patient has been dosed in its Phase 2 pHalcon EoE-201 trial evaluating VOQUEZNA (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis in adults.
The study is a two-part, randomized, double-blind, placebo-controlled trial. Part 1 will enroll 80 adults with endoscopic-confirmed EoE and dysphagia, randomized to VOQUEZNA 20 mg or placebo once daily for 12 weeks. Patients who complete Part 1 may enter a 12-week extension (Part 2), where all participants receive VOQUEZNA 20 mg.
Topline primary and secondary results are anticipated in 2027. The company also noted typical development uncertainties and forward-looking risks related to study conduct, enrollment, outcomes, and future program decisions.
Phathom Pharmaceuticals furnished a press release announcing financial results for the quarter ended September 30, 2025. The release was provided as Exhibit 99.1 to an Item 2.02 report.
Under General Instruction B.2, the information in the report, including Exhibit 99.1, is treated as furnished and not filed.
Phathom Pharmaceuticals (PHAT) reported that additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial of VOQUEZNA (vonoprazan) in Non-Erosive Reflux Disease were published in the American Journal of Gastroenterology. The article, “Vonoprazan Improves Nocturnal Gastroesophageal Reflux Symptoms in Non-Erosive Reflux Disease,” highlights the burden of nighttime GERD symptoms.
In the trial, 772 patients were randomized to VOQUEZNA 10 mg, 20 mg, or placebo for 4 weeks, followed by a 20-week extension with active treatment. Nighttime GERD symptoms affect up to an estimated 80% of patients and are linked to impaired sleep and productivity. The company also included standard forward-looking statement cautions about clinical performance and market acceptance.
Phathom Pharmaceuticals appointed Sanjeev Narula as its Chief Financial and Business Officer and principal financial officer, effective October 6, 2025, replacing Robert Breedlove in the principal financial officer role while he remains principal accounting officer. Mr. Narula will receive an initial annual base salary of $550,000 and be eligible for an annual target bonus equal to 50% of base salary, with a prorated bonus opportunity for 2025.
His employment agreement provides severance if he is terminated without cause or resigns for good reason, including up to 9 months of base salary, a prorated target bonus, certain unpaid bonuses, company-paid COBRA premiums during the severance period, and partial acceleration of time-based equity awards. If such a termination occurs within the defined change in control period, the severance period increases to 18 months, the cash bonus multiple increases to 1.5x target bonus, and all unvested time-based equity awards vest in full, with performance-based awards governed by their own terms.
On October 6, 2025, Phathom granted Mr. Narula stock options to purchase 200,000 shares of common stock vesting over four years and 144,000 restricted stock units vesting in three annual installments, all under the company’s 2019 Incentive Award Plan and subject to continued employment.